Diagnosis and antiviral intervention strategies for mitigating an influenza epidemic

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Moss, Robert ^a   McCaw, James M ^a   McVernon, Jodie ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; CONTROLLED STUDY; FALSE POSITIVE RESULT; HOSPITALIZATION; HUMAN; INFLUENZA; MOLECULAR DIAGNOSIS; PANDEMIC; POLYMERASE CHAIN REACTION; RAPID POINT OF CARE TEST; SENSITIVITY AND SPECIFICITY; STRATEGIC PLANNING; EPIDEMIC; PUBLIC HEALTH SERVICE; TIME;

ANTIVIRAL AGENTS; EPIDEMICS; HUMANS; INFLUENZA, HUMAN; PANDEMICS; POLYMERASE CHAIN REACTION; PUBLIC HEALTH PRACTICE; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 79951538879     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014505     Document Type: Article

References (63)

1. Shortridge KF, (2006) Influenza pandemic preparedness: gauging from EU plans. The Lancet 367: 1374-1375.
2. Mounier-Jack S, Coker RJ, (2006) How prepared is Europe for pandemic influenza? Analysis of national plans. The Lancet 367: 1405-1411.
3. Bishop JF, Murnane MP, Owen R, (2009) Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med 361: 2591-2594.
4. DoHA (2008) The Australian Health Management Plan for Pandemic Influenza 2008. Technical report, Department of Health and Ageing (Australia). Available: http://www.flupandemic.gov.au/internet/panflu/publishing.nsf/Content/ahmppi.
5. Lokuge B, Drahos P, Neville W, (2006) Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option? Med J Aust 184: 16-20.
6. Centers for Disease Control and Prevention (1999) Neuraminidase Inhibitors for Treatment of Influenza A and B Infections. MMWR 48: 1-9.
7. Hurt AC, Barr IG, Hartel G, Hampson AW, (2004) Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Research 62: 37-45.
8. McVernon J, McCaw JM, Nolan TM, (2010) Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response. Aust NZ J Publ Health 34: 113-119.
9. McCaw JM, Wood JG, McCaw CT, McVernon J, (2008) Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS ONE 3: e2362.
10. McCaw JM, McVernon J, (2007) Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemic. Math Biosci 209: 336-360.
11. Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, et al. (2008) Economic Evaluation of Influenza Pandemic Mitigation Strategies in the United States Using a Stochastic Microsimulation Transmission Model. Value in Health 12: 226-233.
12. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, et al. (2006) Strategies for mitigating an influenza pandemic. Nature 442: 448-452.
13. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, et al. (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437: 209-214.
14. Longini I, Halloran M, Nizam A, Yang Y, (2004) Containing pandemic influenza with antiviral agents. Am J Epidemiol 159: 623-33.
15. Bridges CB, Kuehnert M, Hall C, (2003) Transmission of influenza: implications for control in health care settings. Clin Infect Dis 37: 1094-1101.
16. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M, (2007) Transmission of influenza A in human beings. Lancet Infect Dis 7: 257-265.
17. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, et al. (2001) Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285: 748-754.
18. Halloran ME, Hayden FG, Yang Y, Longini IM, Monto AS, (2007) Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 165: 212-221.
19. WHO (2007) WHO Interim Protocol: Rapid operations to contain the initial emergence of pandemic influenza. Technical report, World Health Organisation.
20. WHO (2009) Pandemic influenza preparedness and response. Technical report, World Health Organization.
21. McCaw JM, Wood JG, McBryde ES, Nolan TM, Wu JT, et al. (2009) Understanding Australia's influenza pandemic policy on the strategic use of the antiviral drug stockpile. Med J Aust 191: 136-137.
22. Collins N, Litt J, Moore M, Winzenberg T, Shaw K, (2006) General practice: professional preparation for a pandemic. Med J Aust 185: S66-S99.
23. Swaminathan A, Martin R, Gamon S, Aboltins C, Athan E, et al. (2007) Personal protective equipment and antiviral drug use during hospitalization for suspected avian or pandemic influenza. Emerg Infect Dis 13: 1541-1547.
24. Grayson ML, Johnson PDR, (2009) Australia's influenza containment plan and the swine flu epidemic in Victoria. Med J Aust 191: 150.
25. Eizenberg P, (2009) The general practice experience of the swine flu epidemic in Victoria- lessons from the front line. Med J Aust 191: 151-153.
26. Stuart RL, Cheng AC, Marshall CL, Ferguson JK, (2009) ASID (HICSIG) position statement: infection control guidelines for patients with influenza-like illnesses, including pandemic (H1N1) influenza 2009, in Australian health care facilities. Med J Aust 191: 454-458.
27. Foo H, Blyth C, van Hal S, McPhie K, Ratnamohan M, et al. (2009) Laboratory test performance in young adults during influenza outbreaks at World Youth Day 2008. J Clin Virol 46: 384-386.
28. van Hal SJ, Foo H, Blyth CC, McPhie K, Armstrong P, et al. (2009) Influenza outbreak during Sydney World Youth Day 2008: the utility of laboratory testing and case definitions on mass gathering outbreak containment. PLoS One 4: e6620.
29. Lipsitch M, Riley S, Cauchemez S, Ghani AC, Ferguson NM, (2009) Managing and reducing uncertainty in an emerging influenza pandemic. N Engl J Med.
30. Kelly HA, (2010) A pandemic response to a disease of predominantly seasonal intensity. Med J Aust 192: 1-3.
31. Kelly H, Grant K, (2009) Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14.
32. Catton MG, Druce JD, Birch CJ, (2009) Australia's influenza containment plan and the swine flu epidemic in Victoria. Med J Aust 191: 288.
33. Franco-Paredes C, Carrasco P, Preciado JIS, (2009) The first influenza pandemic in the new millennium: lessons learned hitherto for current control efforts and overall pandemic preparedness. J Immune Based Ther Vaccines 7: 2.
34. Yang Y, Halloran ME, Longini IM, (2009) A bayesian model for evaluating influenza antiviral efficacy in household studies with asymptomatic infections. Biostatistics 10: 390-403.
35. Thursky K, Cordova SP, Smith D, Kelly H, (2003) Working towards a simple case definition for influenza surveillance. J Clin Virol 27: 170-179.
36. Lum ME, McMillan AJ, Brook CW, Lester R, Piers LS, (2009) Impact of pandemic (H1N1) 2009 influenza on critical care capacity in Victoria. Med J Aust 191: 502-506.
37. Kelly HA, Grant KA, Williams S, Fielding J, Smith D, (2009) Epidemiological characteristics of pandemic influenza H1N1 2009 and seasonal influenza infection. Med J Aust 191: 146-149.
38. Edmunds WJ, O'Callaghan CJ, Nokes DJ, (1997) Who mixes with whom? A method to determine the contact patterns of adults that may lead to the spread of airborne infections. Proc Biol Sci 264: 949-957.
39. Edmunds WJ, Kafatos G, Wallinga J, Mossong JR, (2006) Mixing patterns and the spread of close-contact infectious diseases. Emerg Themes Epidemiol 3: 10.
40. Basta NE, Halloran ME, Matrajt L, Longini IM, (2008) Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol 168: 1343-1352.
41. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, et al. (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet.
42. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, et al. (2010) Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328: 357-360.
43. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med.
44. Germann TC, Kadau K, Longini IM, Macken CA, (2006) Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A 103: 5935-5940.
45. Nougairde A, Ninove L, Zandotti C, Salez N, Mantey K, et al. (2010) Novel virus influenza A (H1N1sw) in South-Eastern France, April-August 2009. PLoS One 5: e9214.
46. McBryde ES, Bergeri I, van Gemert C, Rotty J, Headley EJ, et al. (2009) Early transmission characteristics of influenza A(H1N1)v in Australia: Victorian state, 16 May- 3 June 2009. Euro Surveill 14.
47. Eastwood K, Durrheim DN, Massey PD, Kewley C, (2009) Australia's pandemic "protect" strategy: the tension between prevention and patient management. Rural and Remote Health 9: 1288.
48. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S, (2009) Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Medicine 6: e1000085.
49. Lipsitch M, Cohen T, Murray M, Levin BR, (2007) Antiviral resistance and the control of pandemic influenza. PLoS Med 4: e15.
50. Stilianakis N, Perelson A, Hayden F, (1998) Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 177: 863-73.
51. Ferguson N, Mallett S, Jackson H, Roberts N, Ward P, (2003) A population-dynamic model for evaluating the potential spread of resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother 51: 977-990.
52. Debarre F, Bonhoeffer S, Regoes R, (2007) The effect of population structure on the emergence of drug resistance during influenza pandemics. J R Soc Interface 4: 893-906.
53. Xu Y, Allen L, Perelson A, (2007) Stochastic model of an influenza epidemic with drug resistance. J Theor Biol 248: 179-93.
54. Moghadas S, Bowman C, Rost G, Wu J, (2008) Population-wide emergence of antiviral resistance during pandemic influenza. PLoS ONE 3: e1839.
55. Moghadas SM, (2008) Management of drug resistance in the population: influenza as a case study. Proc Biol Sci 275: 1163-1169.
56. Medlock J, Meyers LA, Galvani A, (2009) Optimizing allocation for a delayed influenza vaccination campaign. PLoS Curr Influenza.
57. Medlock J, Galvani AP, (2009) Optimizing influenza vaccine distribution. Science 325: 1705-1708.
58. Australia Post (2009) Annual Report 2008-09. Technical report, Australia Post.
59. Thorn F, (2009) Public health emergency order. Victoria Government Gazette S175.
60. Kmietowicz Z, (2009) England to launch special flu service next week to take pressure off primary care. Br Med J 339: b2932.
61. Lee VJ, Lye DC, Wilder-Smith A, (2009) Combination strategies for pandemic influenza response- a systematic review of mathematical modeling studies. BMC Medicine 7: 76.
62. Kamigaki T, Oshitani H, (2009) Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. PLoS Curr Influenza.
63. Cowling BJ, Lau EHY, Ip DKM, Ho LM, Tsang T, et al. (2010) School closure and mitigation of pandemic (H1N1) 2009, Hong Kong. Emerg Infect Dis 16: 538-541.